Levosimendan Zentiva

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Zentiva (Levosimendan)

Q: What is Levosimendan Zentiva used for?

Levosimendan Zentiva is indicated for the treatment of acute decompensated heart failure in adult patients. It is used to improve cardiac output and relieve symptoms of congestion when conventional therapy is insufficient.

Q: How does Levosimendan work?

Levosimendan sensitises cardiac troponin C to calcium, which enhances myocardial contractility without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing both preload and afterload.

Q: What is the usual dose of Levosimendan?

The dosing regimen is determined by the prescribing clinician based on the patient’s clinical status. Typically, a loading dose may be followed by a continuous intravenous infusion, but exact amounts and duration are individualized.

Q: Is Levosimendan safe in pregnancy or breastfeeding?

Safety data in pregnancy and lactation are limited. Levosimendan should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

Q: How do I order Levosimendan Zentiva from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Q: How does Levosimendan compare with other inotropes?

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. Its combined vasodilatory effect also lowers cardiac workload, offering a distinct therapeutic profile compared with agents such as dobutamine or milrinone.

Q: How should Levosimendan be stored and handled?

Levosimendan solution for injection must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to local regulations.

Q: How is Levosimendan administered?

Levosimendan is given intravenously, usually as an initial loading infusion followed by a continuous maintenance infusion. Administration is performed by qualified healthcare professionals in a monitored setting, with vital signs observed throughout the infusion period.

Q: What are the most serious risks associated with Levosimendan?

The most critical risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential during therapy.

Q: Who should not use Levosimendan?

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, those with known hypersensitivity to the drug, and individuals with severe obstructive cardiomyopathy where increased contractility could be harmful.

Levosimendan, the active ingredient in Levosimendan Zentiva, is a calcium sensitizer presented as a solution for injection for intravenous use. It treats acute decompensated heart failure in adult patients.
GNH India supplies Levosimendan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan acts on the cardiovascular system to improve cardiac performance in acute heart failure settings.
Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium levels. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing cardiac preload and afterload.

Side Effects

Levosimendan may cause a range of adverse reactions.

Common Side Effects

Hypotension: drop in blood pressure, especially during loading dose.
Headache: mild to moderate intensity.
Nausea: occasional gastrointestinal upset.
Tachycardia: increased heart rate.

Serious or Rare Side Effects

Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
Severe hypotension: marked blood pressure fall requiring intervention.
Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion.
Allergic reactions: rash, pruritus, or anaphylaxis.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures.

Blood pressure monitoring: observe for hypotension during and after infusion.
Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with existing conduction disorders.
Renal function assessment: adjust use in severe renal impairment.
Hepatic function assessment: use cautiously in moderate to severe liver disease.
Contraindication in severe hypotension: avoid in patients with systolic BP <90 mmHg.
Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan may interact with several drug classes.

Major Interactions (Avoid)

Concurrent vasodilators (e.g., nitroglycerin): risk of profound hypotension.
Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations.
Other calcium sensitizers: additive inotropic effect can precipitate arrhythmias.

Moderate Interactions (Monitor Closely)

Diuretics: may enhance volume depletion and hypotension.
Beta‑blockers: may blunt desired inotropic response.
ACE inhibitors or ARBs: combined effect on blood pressure requires observation.

Frequently Asked Questions

Levosimendan Zentiva is indicated for the treatment of acute decompensated heart failure in adult patients. It is used to improve cardiac output and relieve symptoms of congestion when conventional therapy is insufficient.

Levosimendan sensitises cardiac troponin C to calcium, which enhances myocardial contractility without increasing intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing both preload and afterload.

The dosing regimen is determined by the prescribing clinician based on the patient’s clinical status. Typically, a loading dose may be followed by a continuous intravenous infusion, but exact amounts and duration are individualized.

Safety data in pregnancy and lactation are limited. Levosimendan should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it is generally avoided unless absolutely necessary.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where needed) and import documentation.

Unlike traditional catecholamine inotropes, Levosimendan increases contractility without raising intracellular calcium, which may reduce the risk of arrhythmias. Its combined vasodilatory effect also lowers cardiac workload, offering a distinct therapeutic profile compared with agents such as dobutamine or milrinone.

Levosimendan solution for injection must be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to local regulations.

Levosimendan is given intravenously, usually as an initial loading infusion followed by a continuous maintenance infusion. Administration is performed by qualified healthcare professionals in a monitored setting, with vital signs observed throughout the infusion period.

The most critical risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions such as anaphylaxis. Prompt recognition and management of these events are essential during therapy.

Levosimendan is contraindicated in patients with systolic blood pressure below 90 mmHg, those with known hypersensitivity to the drug, and individuals with severe obstructive cardiomyopathy where increased contractility could be harmful.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.